Biomarkers of AKI in Patients Receiving Daratumumab

Part of paid clinical trials in Boston, Massachusetts.

Sponsor: Brigham and Women's Hospital
Study ID: NCT06549634
Status: Completed

Conditions

Acute Kidney Injury
Light Chain Nephropathy
Multiple Myeloma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Daratumumab — DRUG
Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration

Study Details

The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI Participants will give urine and blood samples at their normally scheduled lab appointments.